Fig. 2From: Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in KoreaProgression-free survival (a) and overall survival (b) in patients with head and neck cancer treated with immune checkpoint inhibitors. HNSCC head and neck squamous cell carcinoma, NPC nasopharyngeal cancerBack to article page